KalVista Pharmaceuticals’ (KALV) Buy Rating Reaffirmed at Jones Trading
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Jones Trading ...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Analysts
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from ...
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
US-based biopharmaceutical company KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of ...
TD Cowen Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
TD Cowen analyst Stacy Ku maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price target of $30.00.
Stifel Nicolaus Keeps Their Buy Rating on KalVista Pharmaceuticals (KALV)
In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report), ...
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID ...
Finanznachrichten16d
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...
Nasdaq16d
KALVISTA PHARMACEUTICALS Earnings Results: $KALV Reports Quarterly Earnings
KALVISTA PHARMACEUTICALS ($KALV) posted quarterly earnings results on Wednesday, March 12th. The company reported earnings of -$0.92 per share, missing estimates of ...
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update.
Morningstar17d
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update. "Sebetralstat is poised to ...